JP2007537286A - Pparモジュレーターとしての化合物および組成物 - Google Patents

Pparモジュレーターとしての化合物および組成物 Download PDF

Info

Publication number
JP2007537286A
JP2007537286A JP2007513366A JP2007513366A JP2007537286A JP 2007537286 A JP2007537286 A JP 2007537286A JP 2007513366 A JP2007513366 A JP 2007513366A JP 2007513366 A JP2007513366 A JP 2007513366A JP 2007537286 A JP2007537286 A JP 2007537286A
Authority
JP
Japan
Prior art keywords
phenyl
phenoxy
dichloro
acetic acid
isoxazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007513366A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007537286A5 (cg-RX-API-DMAC7.html
Inventor
ロベルト・エップレ
ロス・ルッソ
ミハイ・アジミオアラ
ヨンピン・シェ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IRM LLC
Original Assignee
IRM LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IRM LLC filed Critical IRM LLC
Publication of JP2007537286A publication Critical patent/JP2007537286A/ja
Publication of JP2007537286A5 publication Critical patent/JP2007537286A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2007513366A 2004-05-14 2005-05-12 Pparモジュレーターとしての化合物および組成物 Pending JP2007537286A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57100304P 2004-05-14 2004-05-14
PCT/US2005/016672 WO2005113519A1 (en) 2004-05-14 2005-05-12 Compounds and compositions as ppar modulators

Publications (2)

Publication Number Publication Date
JP2007537286A true JP2007537286A (ja) 2007-12-20
JP2007537286A5 JP2007537286A5 (cg-RX-API-DMAC7.html) 2008-06-26

Family

ID=35428368

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007513366A Pending JP2007537286A (ja) 2004-05-14 2005-05-12 Pparモジュレーターとしての化合物および組成物

Country Status (14)

Country Link
US (1) US7820705B2 (cg-RX-API-DMAC7.html)
EP (1) EP1745027A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007537286A (cg-RX-API-DMAC7.html)
KR (1) KR20070034993A (cg-RX-API-DMAC7.html)
CN (1) CN1984894A (cg-RX-API-DMAC7.html)
AR (1) AR048789A1 (cg-RX-API-DMAC7.html)
AU (2) AU2005245411B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0511099A (cg-RX-API-DMAC7.html)
CA (1) CA2564429A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06013196A (cg-RX-API-DMAC7.html)
PE (1) PE20060357A1 (cg-RX-API-DMAC7.html)
RU (1) RU2408589C2 (cg-RX-API-DMAC7.html)
TW (1) TW200602330A (cg-RX-API-DMAC7.html)
WO (1) WO2005113519A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011522810A (ja) * 2008-06-09 2011-08-04 ルートヴィヒ‐マクシミリアンズ‐ウニヴェルジテート・ミュンヘン タンパク質凝集関連の疾患および/または神経変性性疾患に関係するタンパク質の凝集を阻害するための新規薬物

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1707202A1 (de) * 2005-03-31 2006-10-04 Speedel Experimenta AG Organische Verbindungen
US20070015839A1 (en) * 2005-07-14 2007-01-18 Franco Folli Daily Dosage Regimen for Treating Diabetes, Obesity, Metabolic Syndrome and Polycystic Ovary Syndrome
EP1942921A4 (en) * 2005-10-25 2011-03-09 Merck Sharp & Dohme COMBINATION OF A DIPEPTIDYL-PEPTIDASE-4 HEMMER AND AN ANTIHYPERTENSIVE AGENT FOR THE TREATMENT OF DIABETES AND HYPERTONIA
DE102006014165A1 (de) * 2006-03-24 2007-09-27 Schebo Biotech Ag Neue Isooxazol-Derivate und deren Verwendungen
TW200811164A (en) * 2006-05-12 2008-03-01 Jerini Ag New heterocyclic compounds for the inhibition of integrins and use thereof
WO2008035359A2 (en) * 2006-06-12 2008-03-27 Cadila Healthcare Limited Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives
US20080020014A1 (en) * 2006-07-19 2008-01-24 Paul Consigny Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders
JP5301557B2 (ja) 2007-12-04 2013-09-25 エフ.ホフマン−ラ ロシュ アーゲー イソオキサゾロ−ピリジン誘導体
US7943619B2 (en) * 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
US7618973B2 (en) * 2007-12-04 2009-11-17 Hoffmann-La Roche Inc. Isoxazolo-pyrazine derivatives
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US8785435B2 (en) 2011-10-20 2014-07-22 Hoffmann-La Roche Inc. Solid forms
US8604062B2 (en) 2011-10-20 2013-12-10 Hoffman-La Roche Inc. Process for the preparation of isoxazolyl-methoxy nicotinic acids
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN105030771B (zh) * 2015-04-10 2017-11-17 广州市爱菩新医药科技有限公司 连吡啶异恶唑类化合物作为法尼醇x受体激动剂的应用
CN105622536B (zh) * 2015-12-30 2018-06-29 商丘师范学院 一种三氟甲基化烯基异噁唑化合物及其制备方法和应用
CN105622537A (zh) * 2016-03-01 2016-06-01 青岛大学 一种3,4,5-三取代异恶唑类化合物的合成方法
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
ES2982801T3 (es) 2017-03-28 2024-10-17 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas
KR102692309B1 (ko) 2019-01-15 2024-08-07 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
WO2020172075A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1174841A (en) * 1966-07-25 1969-12-17 Bristol Myers Co A process for the preparation of Substituted Isothiazoles
GB1224568A (en) * 1967-05-16 1971-03-10 American Home Prod Process for preparing alkyl-3,5-disubstituted-isoxazole 4-carboxylates
DE3247454A1 (de) * 1982-12-22 1984-06-28 Laboratorios Bago S.A., Buenos Aires Substituierte 3-phenyl-5-methyl-isoxazol-4-carboxy-anilide, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JPH0665219A (ja) * 1992-06-12 1994-03-08 Bayer Ag 3−アリール置換5−アルキル−イソオキサゾール−4−カルボン酸誘導体の内部寄生虫駆除のための使用、新規な3−アリール置換5−アルキル−イソオキサゾール−4−カルボン酸誘導体、及びそれらの製造方法
WO2001016116A1 (en) * 1999-09-01 2001-03-08 Chemrx Advanced Technologies, Inc. Process for synthesizing isoxazolines and isoxazoles
WO2001096346A1 (en) * 2000-06-14 2001-12-20 Eli Lilly And Company Tricyclic compounds as mrp1-inhibitors
JP2002510625A (ja) * 1998-04-08 2002-04-09 イーライ・リリー・アンド・カンパニー Mrp1の阻害方法
JP2002522425A (ja) * 1998-08-07 2002-07-23 カイロン コーポレイション エストロゲンレセプターモジュレーターとしての置換イソオキサゾール
WO2003015780A2 (en) * 2001-08-15 2003-02-27 Novartis Ag Isoxazolopyridinones and use thereof in the treatment of parkinson's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2088996A (en) * 1935-11-22 1937-08-03 Hoffmann La Roche Double compounds of secondary amides of 3.5-dimethyl-isoxazole-4-carboxylic acid and process for the manufacture of same
GB1203040A (en) * 1967-02-15 1970-08-26 Geigy Ag J R 5-nitro-2-furyl-isoxazoles and compositions thereof
IT1228288B (it) * 1989-01-09 1991-06-07 Zambon Spa Composti ad attivita' antiserotoninica
CA2247439A1 (en) * 1996-02-27 1997-09-04 Sankyo Company, Limited Isoxazole derivatives
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
WO2004024939A2 (en) 2002-09-13 2004-03-25 Georgetown University Ligands for the peroxisome proliferator-activated receptor, and methods of use thereof
ES2308251T3 (es) * 2003-09-12 2008-12-01 Rigel Pharmaceuticals, Inc. Compuestos de quinolina y sus usos.

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1174841A (en) * 1966-07-25 1969-12-17 Bristol Myers Co A process for the preparation of Substituted Isothiazoles
GB1224568A (en) * 1967-05-16 1971-03-10 American Home Prod Process for preparing alkyl-3,5-disubstituted-isoxazole 4-carboxylates
DE3247454A1 (de) * 1982-12-22 1984-06-28 Laboratorios Bago S.A., Buenos Aires Substituierte 3-phenyl-5-methyl-isoxazol-4-carboxy-anilide, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JPH0665219A (ja) * 1992-06-12 1994-03-08 Bayer Ag 3−アリール置換5−アルキル−イソオキサゾール−4−カルボン酸誘導体の内部寄生虫駆除のための使用、新規な3−アリール置換5−アルキル−イソオキサゾール−4−カルボン酸誘導体、及びそれらの製造方法
JP2002510625A (ja) * 1998-04-08 2002-04-09 イーライ・リリー・アンド・カンパニー Mrp1の阻害方法
JP2002522425A (ja) * 1998-08-07 2002-07-23 カイロン コーポレイション エストロゲンレセプターモジュレーターとしての置換イソオキサゾール
WO2001016116A1 (en) * 1999-09-01 2001-03-08 Chemrx Advanced Technologies, Inc. Process for synthesizing isoxazolines and isoxazoles
WO2001096346A1 (en) * 2000-06-14 2001-12-20 Eli Lilly And Company Tricyclic compounds as mrp1-inhibitors
WO2003015780A2 (en) * 2001-08-15 2003-02-27 Novartis Ag Isoxazolopyridinones and use thereof in the treatment of parkinson's disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011522810A (ja) * 2008-06-09 2011-08-04 ルートヴィヒ‐マクシミリアンズ‐ウニヴェルジテート・ミュンヘン タンパク質凝集関連の疾患および/または神経変性性疾患に関係するタンパク質の凝集を阻害するための新規薬物

Also Published As

Publication number Publication date
PE20060357A1 (es) 2006-05-09
AU2005245411A1 (en) 2005-12-01
CA2564429A1 (en) 2005-12-01
CN1984894A (zh) 2007-06-20
KR20070034993A (ko) 2007-03-29
TW200602330A (en) 2006-01-16
BRPI0511099A (pt) 2007-12-26
AU2009202781A1 (en) 2009-07-30
AU2005245411B2 (en) 2009-04-23
AR048789A1 (es) 2006-05-24
EP1745027A4 (en) 2009-06-03
US7820705B2 (en) 2010-10-26
RU2006144124A (ru) 2008-06-20
WO2005113519A1 (en) 2005-12-01
RU2408589C2 (ru) 2011-01-10
MXPA06013196A (es) 2007-02-14
EP1745027A1 (en) 2007-01-24
US20080114044A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
US7820705B2 (en) Compounds and compositions as PPAR modulators
EP1979360B1 (en) Compounds and compositions as ppar modulators
JP2008500355A (ja) Pparモジュレーターとしての化合物および組成物
JP2009525275A (ja) 多環式1,2,3,4−テトラヒドロ−イソキノリン誘導体およびpparモジュレーターとしてのそれらを含む組成物
JP2008500354A (ja) Pparモジュレーターとしての化合物および組成物
AU2007208156A1 (en) Spiro imidazole derivatives as PPAR modulators
CN103906509B (zh) 脑啡肽酶抑制剂
JP2008528700A (ja) Pparモジュレーターとしての化合物および組成物
JP2009514974A (ja) Pparモジュレーターとしての化合物および組成物
JP2007537289A (ja) Pparモジュレーターとしての化合物および組成物
KR20080059635A (ko) Ppar 조절제로서의 화합물 및 조성물
JP2009514973A (ja) Pparモジュレーターとしての化合物および組成物
KR20070030791A (ko) Ppar 조절제로서의 화합물 및 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080502

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110301

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110816